您現在位置:首頁 > 公司概況

遼寧AG6AG生物製藥有限公司成立於2010年,坐落在國家遼寧(本溪)生物醫藥產業基地本溪經濟技術開發區,是以研發、生產胰島素係列產品為一體的現代化生物製藥企業。占地麵積35000平方米、建築麵積20000平方米,現有固定資產近兩億元。

遼寧AG6AG生物製藥有限公司始終以人類健康為宗旨,以服務社會、回報社會為己任。力求在生物製藥領域走出一條創新之路。在不斷引進高科技人才的前提下,已研發出國際領先的基因重組蛋白質藥物重組人胰島素,及其長效類似物甘精胰島素、速效類似物門冬胰島素。

遼寧AG6AG生物製藥有限公司依靠政策優勢、區域優勢,以及現有的人才、科技優勢,在短時間內使企業逐步發展成技術密集、管理規範、產品一流、質量可靠地現代化製藥企業。

遼寧AG6AG生物製藥有限公司自主研發生產的胰島素類係列產品與國際國內市場銷售的同類產品相比,具有以下特點:
1.
純度高,雜質種類和含量不高於市場銷售的同類產品。
2. 質量標準高,滿足歐盟、美國等多個現行藥典標準。
3. 生產工藝節能環保,獨特的生產工藝,減少了汙染物排放,提高了產品收率。
LiaoNingBoao Biological Pharmaceutical Co.,Ltd founded in 2010,is located in the Chinesebiologically pharmaceutical industrial base,EconomicTechnological Development District,Benxi,Liaoning. Boao is a research anddevelopment,the production of insulin products and APIs for the integration ofmodern biological science and technology enterprise.It covers an area of 35,000square meters and its area of structure is 20,000 square meters,its fixedassets is nearly 200 million Yuan.

LiaoNingBoao Biological Pharmaceutical Co.,Ltd is always working for human health and servingfor the society,and take repaying society as our responsibility.We are strivingfor walking out an innovation road in the biological pharmaceutical field.Under the premise of introducing of high-tech talents, ourcompany has been developed the international advanced gene recombinant protein pharceutical:recombinant human insulin and its long-acting analogue insulin glargine、quick-actinganalogue insulin aspart.

LiaoNingBoao Biological Pharmaceutical Co.,Ltd relys on the policy advantages andregional and exsisting talents and technological advantages to make itself developinto a modern technology-intensive  pharceutical enterprise which has standardizedmanagement and produce first-rate and reliable quality products.

Compared with the international and domesticmarket, our series of independent research and development insulin products hasthe following features:

1. Thepurity is high. Our products’ impurities spots are not higher than the similarproducts in the market

2. Thequality standard is high. It meets European Union and the United States’ multiplepharmacopoeia criterion in force.

3. Themanufacturing technique is saving energy and protecting environment.The unique techniquereduces the pollutant discharge and increases the production yeild at the sametime.